LinkedIn
WebsiteIntroduction
Annovis Bio Inc. (ticker: ANVS) is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania. Founded in May 2008 by Dr. Maria L. Maccecchini, Annovis focuses on developing oral, brain-penetrant therapies aimed at slowing or halting neuronal loss in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. Its lead compound, buntanetap, is designed to inhibit the translation of multiple neurotoxic proteins, with the goal of restoring cognitive and motor function.
Corporate Structure
Annovis Bio is listed on the New York Stock Exchange under the symbol ANVS. According to LinkedIn, the company employs between 2 and 10 people. Key members of the leadership team include:
- Maria L. Maccecchini, PhD – Founder and Chief Executive Officer, with a background at Symphony Pharmaceuticals/Annovis and Bachem Bioscience
- Mark Guerin, CPA, CMA, CFM – Chief Financial Officer, appointed in 2025, previously CFO at Onconova Therapeutics (now Traws Pharma)
- Dr. Fang and Dr. Christie – Senior scientific leaders with extensive backgrounds in neurodegenerative disease research and pharmaceutical process development
Neurodegenerative therapies by Milad Fakurian
Recent Developments and News
On October 2, 2025, Citadel Advisors LLC and its affiliates filed a Schedule 13G reporting a 3.1 percent stake (5,828,555 shares) in Annovis Bio as of September 29, 2025. A subsequent Schedule 13G on October 6, 2025, showed related entities holding 4.7 percent (1,379,861 shares) of the company’s outstanding stock as of July 30, 2025.
Annovis is actively enrolling patients in a pivotal Phase 3 trial of buntanetap in early Alzheimer’s disease across approximately 100 sites in the U.S. and Europe. Phase 2a and Phase 3 Parkinson’s disease studies have demonstrated statistically significant improvements in cognitive scores (MMSE) and motor assessments (MDS-UPDRS) versus placebo. A publication by Fang et al. (2022) outlines early safety and efficacy data in both Alzheimer’s and Parkinson’s patients.
Financial and Strategic Analysis
As of market close on October 10, 2025, ANVS shares traded at USD 1.70, down 22.73 percent on the day, with a volume of 2,987,321 shares. Key metrics include:
| Metric | Value |
|---|---|
| 52-Week Range | USD 1.11 – USD 10.54 |
| Market Capitalization | ~USD 33 million |
| Average Daily Volume (10 D) | ~1.12 million shares |
| Cash (MRQ) | USD 17.13 million |
| Levered Free Cash Flow (TTM) | –USD 16.45 million |
| EPS (TTM) | –USD 2.10 |
| Debt/Equity (MRQ) | Not reported |
Annovis Bio reported no material debt and has approximately USD 17 million in cash, which may support its operations in the near term. The presence of institutional ownership by Citadel and other investors indicates external interest in the company, which could influence stock volatility around significant filings or trading activity.
Market Position and Industry Context
The global market for Alzheimer’s and Parkinson’s treatments is characterized by high unmet needs and competition among companies pursuing various therapeutic approaches. Annovis is differentiated by buntanetap’s multi-protein translational inhibition mechanism, supported by preclinical studies conducted at institutions including the Karolinska Institute and Harvard University. Its small organizational size and market capitalization under USD 50 million classify it as a specialized, early-stage company. Key industry catalysts include the timing of pivotal trial data, potential licensing agreements, and the regulatory review processes for new neurodegenerative treatments.
tl;dr
On October 10, 2025, ANVS shares closed at USD 1.70 (–22.73 percent), amid significant trading volume and recent SEC Schedule 13G filings showing Citadel entities holding 3.1–4.7 percent stakes. Patient enrollment is underway in a pivotal Phase 3 Alzheimer’s trial of buntanetap, with previous Phase 2a/3 data indicating improvements in both Alzheimer’s and Parkinson’s programs. Upcoming milestones include completion of full enrollment, data readouts, and potential financing or collaboration announcements.
